PLAINSBORO, N.J., Aug. 17, 2017 -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will present at the Wells Fargo Healthcare Conference and the Morgan Stanley Healthcare Conference in September.
- On Thursday, September 7, 2017 at 10:00 a.m. ET, Glenn Coleman, chief financial officer and corporate vice president of International, will present at the Wells Fargo Healthcare Conference in Boston, MA. A live audio webcast of the presentation can be accessed at Integra’s Investor Relations website at http://investor.integralife.com/.
- On Tuesday, September 12, 2017 at 2:05 p.m. ET, Peter Arduini, president and chief executive officer, will present at the Morgan Stanley Healthcare Conference in New York City. A live audio webcast of the presentation can be accessed at Integra’s Investor Relations website at http://investor.integralife.com/.
About Integra
Integra LifeSciences (NASDAQ:IART) is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies. For more information, please visit www.integralife.com
Statements made at the upcoming conferences may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2016 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts: Integra LifeSciences Holdings Corporation Investor Relations: Michael Beaulieu Director, Investor Relations (609) 750-2827 [email protected]


Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Shell M&A Chief Exits After BP Takeover Proposal Rejected
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
OpenAI Explores Massive Funding Round at $750 Billion Valuation
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 



